Abstract | OBJECTIVE: PATIENTS AND METHODS: Chemo-naïve adult patients with a performance status (PS) of 0-2 and adequate organ function were eligible. Patients received cisplatin 20mg/m(2) i.v. daily for three consecutive days, etoposide 75mg/m(2) i.v. daily for three consecutive days and irinotecan 120mg/m(2) i.v. on day 2, every 21 days for six to eight cycles. Administration of G-CSF was given in the presence of febrile neutropenia and as a 5-day prophylaxis around the recorded nadir day in patients who developed grades 3-4 neutropenia. RESULTS: Fifty-six patients were assessable. The median age was 62.2 years; 96.4% had PS 0-1, 33.5% had >3 metastatic sites. The overall response rate was 80.4% with 8 (14.3%) patients achieving a complete response. The median time to tumor progression was 7.8 months [95% confidence interval (CI), 7.1-8.6 months] with a median survival of 15.1 months [95% CI, 9.7-20.5 months] and 1-year survival rate of 56.5%. One patient died from toxicity. Grades 3-4 neutropenia occurred in 37.5% of patients, grades 3-4 thrombocytopenia occurred in 10.9% of patients and 11 (19.6%) patients developed febrile neutropenia. Grades 3-4 non-hematological toxicities were primarily nausea- vomiting 3.6%, diarrhea 7.1% and fatigue 3.6%. CONCLUSION: This study strongly suggests that cisplatin, etoposide and irinotecan combination is very effective for the treatment of E-SCLC with good safety profile. The triplet regimen currently seems a promising regimen and has to be further explored in phase III trials.
|
Authors | D Pectasides, E Samantas, G Fountzilas, E Briasoulis, P Kosmidis, D Skarlos, M A Dimopoulos, H P Kalofonos, T Economopoulos, K Syrigos |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 58
Issue 3
Pg. 355-61
(Dec 2007)
ISSN: 0169-5002 [Print] Ireland |
PMID | 17698241
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Etoposide
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Adult
- Aged
- Camptothecin
(adverse effects, analogs & derivatives, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, pathology)
- Cisplatin
(adverse effects, therapeutic use)
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Etoposide
(adverse effects, therapeutic use)
- Female
- Humans
- Irinotecan
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Survival Rate
|